Novavax

NVAX
$200.07 -0.64 (-0.32 %)
NASDAQ: Здравоохранение Биотехнологии
Рейтинг Finrange
Статус: -
31 %
Оценка компании, которая составлена на основе анализа всех областей бизнеса компании Стать PRO

График котировок Novavax

Последние новости Novavax

What’s Next For Novavax Stock After A Large 48% Rise In A Month?

Novavax Files for Interim Authorization of Covid-19 Vaccine in Singapore

Novavax Files for Interim Authorization of Covid-19 Vaccine in Singapore

Will Novavax Stock Rise Further With E.U. Decision In The Offing?

European Regulator Starts Assessing Novavax’s Covid Vaccine—Stock Jumps 8%

Novavax Shares Higher After EMA Begins Evaluating Application for Covid-19 Vaccine

Novavax Shares Higher After EMA Begins Evaluating Application for Covid-19 Vaccine

Регулятор ЕС получил заявку на одобрение вакцины американской компании Novavax

Novavax and Serum Institute of India win EUA for COVID-19 vaccine in the Philippines

Novavax and SII Get Emergency Use Authorization for Covid-19 Vaccine in the Philippines

Novavax and Serum Institute of India win EUA for COVID-19 vaccine in the Philippines

Novavax and SII Get Emergency Use Authorization for Covid-19 Vaccine in the Philippines

Novavax and Serum Institute of India win EUA for COVID-19 vaccine in the Philippines

Should You Buy Novavax Stock As It Wins Its First Regulatory Approval?

Novavax Up 13% on Indonesia Vaccine Approval, Regulatory Progress for Canada and Europe

Novavax Up 13% on Indonesia Vaccine Approval, Regulatory Progress for Canada and Europe

Novavax Covid-19 Vaccine Gets First Authorization, in Indonesia

Novavax’s Covid-19 Vaccine Gets Its First Authorization—and More Could Come Soon

Novavax’s Covid-19 Vaccine Gets Its First Authorization—and More Could Come Soon

Novavax’s Covid-19 Vaccine Gets Its First Authorization—and More Could Come Soon

Фундаментальный анализ Novavax

Показатель Компания Отрасль
P/E (LTM)

Показывает за сколько лет при прибыли за последние 12 месяцев окупятся вложения инвестора в компанию.

Подробнее
-13.91 10.55
P/BV (LTM)

Показывает отношение рыночной цены акции к текущей балансовой стоимости.

Подробнее
23.84 8.43
EV/EBITDA (LTM)

Представляет собой отношение стоимости компании к полученной ею прибыли до уплаты налогов EBITDA за последние 12 месяцев.

Подробнее
-14.55 8.24
Net Debt/EBITDA (LTM)

Коэффициент долговой нагрузки компании, который показывает, как долго компании потребуется работать при денежном потоке за последние 12 месяцев, чтобы погасить собственный долг.

Подробнее
-0.0900 0.43
ROE (LTM)

Показывает эффективность использования акционерного капитала компанией. Другими словами, ROE показывает сколько чистой прибыли за последние 12 месяцев приносит компания на вложенный капитал.

Подробнее
-233.03 12.22

Сводный анализ Novavax

Изменение цены Novavax за год

76.59$ 331.68$
Мин Макс

Выручка и чистая прибыль Novavax

Последние новости Novavax

What’s Next For Novavax Stock After A Large 48% Rise In A Month?

Novavax Files for Interim Authorization of Covid-19 Vaccine in Singapore

Novavax Files for Interim Authorization of Covid-19 Vaccine in Singapore

Will Novavax Stock Rise Further With E.U. Decision In The Offing?

European Regulator Starts Assessing Novavax’s Covid Vaccine—Stock Jumps 8%

Novavax Shares Higher After EMA Begins Evaluating Application for Covid-19 Vaccine

Novavax Shares Higher After EMA Begins Evaluating Application for Covid-19 Vaccine

Регулятор ЕС получил заявку на одобрение вакцины американской компании Novavax

Novavax and Serum Institute of India win EUA for COVID-19 vaccine in the Philippines

Novavax and SII Get Emergency Use Authorization for Covid-19 Vaccine in the Philippines

Novavax and Serum Institute of India win EUA for COVID-19 vaccine in the Philippines

Novavax and SII Get Emergency Use Authorization for Covid-19 Vaccine in the Philippines

Novavax and Serum Institute of India win EUA for COVID-19 vaccine in the Philippines

Should You Buy Novavax Stock As It Wins Its First Regulatory Approval?

Novavax Up 13% on Indonesia Vaccine Approval, Regulatory Progress for Canada and Europe

Novavax Up 13% on Indonesia Vaccine Approval, Regulatory Progress for Canada and Europe

Novavax Covid-19 Vaccine Gets First Authorization, in Indonesia

Novavax’s Covid-19 Vaccine Gets Its First Authorization—and More Could Come Soon

Novavax’s Covid-19 Vaccine Gets Its First Authorization—and More Could Come Soon

Novavax’s Covid-19 Vaccine Gets Its First Authorization—and More Could Come Soon